These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 9341905)

  • 1. C-terminal modifications of histidyl-N-benzylglycinamides to give improved inhibition of Ras farnesyltransferase, cellular activity, and anticancer activity in mice.
    McNamara DJ; Dobrusin E; Leonard DM; Shuler KR; Kaltenbronn JS; Quin J; Bur S; Thomas CE; Doherty AM; Scholten JD; Zimmerman KK; Gibbs BS; Gowan RC; Latash MP; Leopold WR; Przybranowski SA; Sebolt-Leopold JS
    J Med Chem; 1997 Oct; 40(21):3319-22. PubMed ID: 9341905
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel conformationally extended naphthalene-based inhibitors of farnesyltransferase.
    Burns CJ; Guitton JD; Baudoin B; Lelièvre Y; Duchesne M; Parker F; Fromage N; Commerçon A
    J Med Chem; 1997 Jun; 40(12):1763-7. PubMed ID: 9191950
    [No Abstract]   [Full Text] [Related]  

  • 3. Dual protein farnesyltransferase-geranylgeranyltransferase-I inhibitors as potential cancer chemotherapeutic agents.
    deSolms SJ; Ciccarone TM; MacTough SC; Shaw AW; Buser CA; Ellis-Hutchings M; Fernandes C; Hamilton KA; Huber HE; Kohl NE; Lobell RB; Robinson RG; Tsou NN; Walsh ES; Graham SL; Beese LS; Taylor JS
    J Med Chem; 2003 Jul; 46(14):2973-84. PubMed ID: 12825937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-thiol farnesyltransferase inhibitors: FTase-inhibition and cellular activity of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors.
    Mitsch A; Bergemann S; Gust R; Sattler I; Schlitzer M
    Arch Pharm (Weinheim); 2003 Jul; 336(4-5):242-50. PubMed ID: 12916059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationship of 3-substituted N-(pyridinylacetyl)-4- (8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene )- piperidine inhibitors of farnesyl-protein transferase: design and synthesis of in vivo active antitumor compounds.
    Njoroge FG; Vibulbhan B; Rane DF; Bishop WR; Petrin J; Patton R; Bryant MS; Chen KJ; Nomeir AA; Lin CC; Liu M; King I; Chen J; Lee S; Yaremko B; Dell J; Lipari P; Malkowski M; Li Z; Catino J; Doll RJ; Girijavallabhan V; Ganguly AK
    J Med Chem; 1997 Dec; 40(26):4290-301. PubMed ID: 9435898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferase.
    Williams TM; Ciccarone TM; MacTough SC; Bock RL; Conner MW; Davide JP; Hamilton K; Koblan KS; Kohl NE; Kral AM; Mosser SD; Omer CA; Pompliano DL; Rands E; Schaber MD; Shah D; Wilson FR; Gibbs JB; Graham SL; Hartman GD; Oliff AI; Smith RL
    J Med Chem; 1996 Mar; 39(7):1345-8. PubMed ID: 8691462
    [No Abstract]   [Full Text] [Related]  

  • 7. Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferase.
    Lingham RB; Silverman KC; Jayasuriya H; Kim BM; Amo SE; Wilson FR; Rew DJ; Schaber MD; Bergstrom JD; Koblan KS; Graham SL; Kohl NE; Gibbs JB; Singh SB
    J Med Chem; 1998 Nov; 41(23):4492-501. PubMed ID: 9804689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity.
    Leftheris K; Kline T; Vite GD; Cho YH; Bhide RS; Patel DV; Patel MM; Schmidt RJ; Weller HN; Andahazy ML; Carboni JM; Gullo-Brown JL; Lee FY; Ricca C; Rose WC; Yan N; Barbacid M; Hunt JT; Meyers CA; Seizinger BR; Zahler R; Manne V
    J Med Chem; 1996 Jan; 39(1):224-36. PubMed ID: 8568812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors.
    Lombardo LJ; Camuso A; Clark J; Fager K; Gullo-Brown J; Hunt JT; Inigo I; Kan D; Koplowitz B; Lee F; McGlinchey K; Qian L; Ricca C; Rovnyak G; Traeger S; Tokarski J; Williams DK; Wu LI; Zhao Y; Manne V; Bhide RS
    Bioorg Med Chem Lett; 2005 Apr; 15(7):1895-9. PubMed ID: 15780629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The development of protein farnesyltransferase inhibitors as signaling-based anticancer agents.
    Ohkanda J; Blaskovich MA; Sebti SM; Hamilton AD
    Prog Cell Cycle Res; 2003; 5():211-7. PubMed ID: 14593715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent and selective non-cysteine-containing inhibitors of protein farnesyltransferase.
    Augeri DJ; O'Connor SJ; Janowick D; Szczepankiewicz B; Sullivan G; Larsen J; Kalvin D; Cohen J; Devine E; Zhang H; Cherian S; Saeed B; Ng SC; Rosenberg S
    J Med Chem; 1998 Oct; 41(22):4288-300. PubMed ID: 9784104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ras farnesyltransferase: a new therapeutic target.
    Leonard DM
    J Med Chem; 1997 Sep; 40(19):2971-90. PubMed ID: 9301658
    [No Abstract]   [Full Text] [Related]  

  • 14. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and in vivo analysis of potent non-thiol inhibitors of farnesyl protein transferase.
    Anthony NJ; Gomez RP; Schaber MD; Mosser SD; Hamilton KA; O'Neil TJ; Koblan KS; Graham SL; Hartman GD; Shah D; Rands E; Kohl NE; Gibbs JB; Oliff AI
    J Med Chem; 1999 Aug; 42(17):3356-68. PubMed ID: 10464022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solid-phase synthesis and biological evaluation of a pepticinnamin E library.
    Thutewohl M; Kissau L; Popkirova B; Karaguni IM; Nowak T; Bate M; Kuhlmann J; Müller O; Waldmann H
    Angew Chem Int Ed Engl; 2002 Oct; 41(19):3616-20; 3516. PubMed ID: 12370908
    [No Abstract]   [Full Text] [Related]  

  • 17. Second-generation peptidomimetic inhibitors of protein farnesyltransferase demonstrating improved cellular potency and significant in vivo efficacy.
    O'Connor SJ; Barr KJ; Wang L; Sorensen BK; Tasker AS; Sham H; Ng SC; Cohen J; Devine E; Cherian S; Saeed B; Zhang H; Lee JY; Warner R; Tahir S; Kovar P; Ewing P; Alder J; Mitten M; Leal J; Marsh K; Bauch J; Hoffman DJ; Sebti SM; Rosenberg SH
    J Med Chem; 1999 Sep; 42(18):3701-10. PubMed ID: 10479301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent, selective, and orally bioavailable tricyclic pyridyl acetamide N-oxide inhibitors of farnesyl protein transferase with enhanced in vivo antitumor activity.
    Njoroge FG; Vibulbhan B; Pinto P; Bishop WR; Bryant MS; Nomeir AA; Lin C; Liu M; Doll RJ; Girijavallabhan V; Ganguly AK
    J Med Chem; 1998 May; 41(10):1561-7. PubMed ID: 9572881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of parathyroid hormone-related peptide by the Ras oncogene: role of Ras farnesylation inhibitors as potential therapeutic agents for hypercalcemia of malignancy.
    Aklilu F; Park M; Goltzman D; Rabbani SA
    Cancer Res; 1997 Oct; 57(20):4517-22. PubMed ID: 9377563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
    Morgan MA; Sebil T; Aydilek E; Peest D; Ganser A; Reuter CW
    Br J Haematol; 2005 Sep; 130(6):912-25. PubMed ID: 16156861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.